NCPA 2026 speakers urge pharmacists to lead peptide talks pending FDA action
Community pharmacists were told to field patient questions on peptide products while the agency's position on the category remains unresolved.
DO
By Daniel Okafor · Regulatory Correspondent
Oct 16 14:00 ETSource: Drug Topics
The wire
- 01At NCPA 2026, speakers told community pharmacists to guide patient conversations about peptide products while FDA action on the category is still pending.
- 02Pharmacists are the front line for patients arriving with questions about gray-market and compounded peptides, and counseling gaps fall to them in the absence of federal clarity.
- 03Details of any forthcoming FDA position were not specified; the session summary is brief and the timing of agency action remains unknown.
From the source
Read at drugtopics.comPharmacists Must Guide Peptide Talks Pending FDA Action | NCPA 2026
